Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

APWU adds new benefits and enhances old plans for 2010

APWU Health Plan is proud to announce our new rates and benefits for 2010. Our exceptionally rated High Option sees a four percent increase in it's rate, while the versatile Consumer Driven Option sees a zero percent increase.

3 Oct 2009

Mothers must heal physically and psychologically from the first stillbirth before conceiving again

Women who experience a stillbirth in their first pregnancy may be at higher risk for complications or adverse outcomes in their next pregnancy, according to a Kaiser Permanente study that appears online in the October issue of the American Journal of Obstetrics and Gynecology.

3 Oct 2009

Arginetix raises funds for development programs

Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The company is developing small molecule inhibitors of the enzyme arginase for the treatment of endothelial dysfunction, including pulmonary arterial hypertension, atherosclerosis and asthma.

2 Oct 2009

sNDA for Clonicel submitted to the FDA

Addrenex Pharmaceuticals and Sciele Pharma, Inc., a Shionogi company today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

2 Oct 2009

Stress linked to ischemic strokes

Strong links have been uncovered between stress and ischemic strokes. Researchers writing in the open access journal BMC Medicine have carried out the first study into the correlation between self-reported feelings of prolonged psychological stress and different stroke subtypes.

1 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Addrenex submits a sNDA to the FDA for Clonicel

Sciele Pharma, Inc., a Shionogi company, and Addrenex Pharmaceuticals today announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) for Clonicel (modified-release clonidine) to treat attention deficit hyperactivity disorder (ADHD).

1 Oct 2009

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

Former professional players have fewer risks of heart attacks

Former professional football players with large bodies don't appear to have the same risk factors for heart disease as their non-athletic counterparts, UT Southwestern Medical Center researchers have found in studying a group of National Football League (NFL) alumni.

30 Sep 2009

SunTech Medical announces independent validation of SunTech 247 blood pressure monitor

SunTech Medical announces the independent validation of the SunTech 247 blood pressure monitor to appear in the October issue of Blood Pressure Monitoring.

30 Sep 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Poor kidney function can affect brain activities

A new study published in the medical journal Neurology suggests that impaired kidney function is a risk factor for cognitive decline in old age.

29 Sep 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

Cardiovascular disease: Major cause of death in Europe

Despite the decline of heart disease mortality registered in the past 30 years, cardiovascular disease (CVD) remains the N.1 killer in Europe and in the World. In the EU, experts reveal that striking disparities still exist between countries not only in terms of CVD incidence, but also with regard to national prevention policies.

25 Sep 2009

Investment in preventative healthcare is vital during recession: Experts

In these economically challenging times, many experts say it is vital to invest in preventative healthcare. Better overall health means lower medical bills.

25 Sep 2009

Health policy research roundup

In this brief, researchers analyze the cost burden associated with excess rates of diseases such as diabetes, hypertension, stroke and renal disease among Hispanics and African Americans relative to non-Hispanic whites. The study predicts that in 2009, "Medicare alone will spend an extra $15.6 billion while private insurers will incur $5.1 billion in additional costs due to elevated rates of chronic illness among African Americans and Hispanics."

25 Sep 2009

Children with minimal change nephrotic syndrome can be treated with prednisone

A kidney condition that can arise in children and was until recently believed to disappear after puberty may persist into adulthood and cause significant long-term complications, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that better treatment options are needed for children with the disorder, called minimal change nephrotic syndrome.

25 Sep 2009

Rio Grande Dermatology offers eyelash drugs for $99

Many women desire to have thicker and longer eyelashes. Previously this could only be accomplished with the use of fake lashes. However, due to the discovery of a desirable side effect of a glaucoma drug, Latisse was born. Rio Grande Dermatology, providers of comprehensive dermatology treatments for the Albuquerque metropolitan area, is proud to offer this highly anticipated "eyelash drug" for an introductory price of $99 dollars.

24 Sep 2009

Mayo Clinic Health Manager users have access to blood pressure trackers

As part of Mayo Clinic and Microsoft Corp.'s shared vision to help families take better care of their health, the two companies have made enhancements to Mayo Clinic Health Manager, a free online application designed to help people organize and better manage their health. People with conditions such as hypertension and high cholesterol will now have access to a variety of trackers and up-to-date information to help keep their conditions under control.

24 Sep 2009